Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Las Vegas Cancer Center-Henderson — Henderson, Nevada
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Nevada: - Renown Regional Medical Center — Reno, Nevada
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Las Vegas Cancer Center-Henderson — Henderson, Nevada
- OptumCare Cancer Care at Seven Hills — Henderson, Nevada
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Nevada: - Renown Medical Group - Oncology/Hematology /ID# 247942 — Reno, Nevada
Phase 3 Recruiting Industry
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in Nevada: - Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037) — Reno, Nevada
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in Nevada: - Research Site — Las Vegas, Nevada
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Nevada: - Renown Regional Medical Center — Reno, Nevada
Phase 3 Recruiting Industry
This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions for making proteins, and this change le…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Nevada: - Cancer Care Specialists — Reno, Nevada
Phase 3 Recruiting Industry
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan an…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06170788
Sites in Nevada: - Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134) — Reno, Nevada
Phase 2, Phase 3 Recruiting Industry
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity "when telisotuzumab adizutecan i…
Sponsor: AbbVie
NCT ID: NCT07005102
Sites in Nevada: - Renown Regional Medical Center /ID# 276049 — Reno, Nevada
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Nevada: - OptumCare Cancer Care at Seven Hills — Henderson, Nevada
- OptumCare Cancer Care at Charleston — Las Vegas, Nevada
- OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Nevada: - OptumCare Cancer Care at Seven Hills — Henderson, Nevada
- OptumCare Cancer Care at Charleston — Las Vegas, Nevada
- OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Nevada: - Women's Cancer Center of Nevada — Las Vegas, Nevada
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Nevada: - Research Site 110 — Las Vegas, Nevada
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Sponsor: IDEAYA Biosciences
NCT ID: NCT05787587
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
Phase 1 Recruiting Industry
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally …
Sponsor: Amgen
NCT ID: NCT06333951
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
Recruiting Academic/Other
This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess s…
Sponsor: Addario Lung Cancer Medical Institute
NCT ID: NCT06486428
Sites in Nevada: - Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html — Multiple Locations, Nevada
Recruiting Industry
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-c…
Sponsor: Freenome Holdings Inc.
NCT ID: NCT06122077
Sites in Nevada: - Renown Regional Medical Center — Reno, Nevada